Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
BioMarin Pharmaceutical
Acquired Company
Alesta Therapeutics
San RafaelBiotechnologyBiotechnologyHealth CareTherapeuticsDescription
BioMarin Pharmaceutical Inc. has successfully completed its acquisition of Alesta Therapeutics, finalizing the deal on September 1, 2026. Alesta’s lead clinical-stage program, ALE1, is a potential oral therapy for hypophosphatasia. The acquisition allows BioMarin to enhance its pipeline with this innovative treatment aimed at a rare genetic bone disease.
Fundz sees it the moment BioMarin Pharmaceutical makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Alesta Therapeutics?
Alesta Therapeutics was acquired by BioMarin Pharmaceutical, based in San Rafael. The deal was reported on October 14, 2026. BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. BioMarin Pharmaceutical is publicly traded (BMRN) and operates in Biotechnology.
When did BioMarin Pharmaceutical acquire Alesta Therapeutics?
BioMarin Pharmaceutical's acquisition of Alesta Therapeutics was reported on October 14, 2026. BioMarin Pharmaceutical Inc. has successfully completed its acquisition of Alesta Therapeutics, finalizing the deal on September 1, 2026. Alesta’s lead clinical-stage program, ALE1, is a potential oral therapy for hypophosphatasia. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alesta Therapeutics do?
Alesta Therapeutics is a biotechnology company focused on developing therapies for rare genetic diseases. The company is engaged in advancing innovative treatments and conducting clinical trials to find effective solutions for serious health conditions. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.